Affiliation:
1. Department of Nutrition Faculty of Medicine Montreal QC Canada
2. CHU Sainte‐Justine Research Center Montreal QC Canada
3. Cystic Fibrosis Clinic CHU Sainte‐Justine Montreal QC Canada
4. Lung Transplant Program Centre Hospitalier de l'Université de Montréal (CHUM) Montreal QC Canada
Abstract
AbstractCystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding for the ion channel cystic fibrosis transmembrane conductance regulator (CFTR). The management of CF disease has evolved in recent decades from treating downstream disease manifestations affecting the airways, the lungs and the gastrointestinal system to addressing the CFTR gene defect. The advent of CFTR modulators, which correct the functionality of the defective CFTR, contributes to reshaping the landscape of CF demographics, prognosis and therapies, including nutritional management. A spectrum of clinical manifestations is emerging within the same patient population where undernutrition and nutritional deficiencies coexist with excessive weight gain and metabolic derangements. Such contrasting presentations challenge current practices, require adjustments to traditional approaches, and involve more individualised interventions. This narrative review examines the current state of knowledge on the nutritional management of people living with cystic fibrosis from early life to adulthood in the era of CFTR modulation.
Subject
Nutrition and Dietetics,Medicine (miscellaneous)
Reference158 articles.
1. Cystic fibrosis
2. Cystic Fibrosis Foundation.https://www.cff.org/managing-cf/cftr-modulator-therapies(2023). Accessed July 6 2023.
3. Vertex Pharmaceuticals Incorporated.https://www.vrtx.com/medicines/our-approved-medicines/(2023). Accessed July 6 2023.
4. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles